Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Egusquiaguirre SP"'
Autor:
Tošić I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Biochemistry, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Heppler LN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Egusquiaguirre SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Boehnke N; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Correa S; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Costa DF; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Moore EAG; Department of Chemistry, Molecular and Cell Biology, University of California at Berkeley, Berkeley, Massachusetts., Pal S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Richardson DS; Harvard Center for Biological Imaging, Harvard University, Cambridge, Massachusetts., Ivanov AR; Department of Chemistry and Chemical Biology, Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, Massachusetts., Haas-Kogan DA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Nomura DK; Department of Chemistry, Molecular and Cell Biology, University of California at Berkeley, Berkeley, Massachusetts., Hammond PT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.; Institute for Soldier Nanotechnology, Massachusetts Institute of Technology, Cambridge, Massachusetts., Frank DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. david_frank@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 726-738. Date of Electronic Publication: 2021 Feb 03.
Autor:
Pintado-Berninches L; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Montes-Worboys A; ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain., Manguan-García C; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Arias-Salgado EG; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain., Serrano A; Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.; CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain., Fernandez-Varas B; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain., Guerrero-López R; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Iarriccio L; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain., Planas L; ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain., Guenechea G; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, Spain., Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain., Hernandez RM; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain., Luis Pedraz J; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), CIBER-BBN, Vitoria-Gasteiz, Spain., Cortijo J; Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain.; CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain., Sastre L; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Molina-Molina M; ILD Unit, Pneumology Department, University Hospital of Bellvitge, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.; CIBER of Respiratory diseases (CIBERES), Health Institute Carlos III, Madrid, Spain., Perona R; Instituto de Investigaciones Biomédicas, CSIC/UAM, IDIPaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Mar; Vol. 35 (3), pp. e21422.
Autor:
Egusquiaguirre SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Tošić I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Jiang K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Walker SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Nicolais M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Saw TY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Xiang M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Bartel K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Nelson EA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States., Frank DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States. Electronic address: david_frank@dfci.harvard.edu.
Publikováno v:
Neoplasia (New York, N.Y.) [Neoplasia] 2020 Jan; Vol. 22 (1), pp. 47-59. Date of Electronic Publication: 2019 Nov 22.
Autor:
Pintado-Berninches L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain.; Advanced Medical Projects, Madrid, Spain., Fernandez-Varas B; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain., Benitez-Buelga C; National Center for Cancer Research, CNIO, Madrid, Spain., Manguan-Garcia C; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain.; CIBER de Enfermedades Raras, Madrid, Spain., Serrano-Benitez A; Centro Andaluz de Biologia Molecular y Medicina regenerativa (CABIMER) - CSIC, Universidad de Sevilla, Universidad Pablo de Olavide, Sevilla, Spain., Iarriccio L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain.; Advanced Medical Projects, Madrid, Spain., Carrillo J; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain., Guenechea G; CIBER de Enfermedades Raras, Madrid, Spain.; Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain., Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Hernández RM; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Arias-Salgado EG; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain.; Advanced Medical Projects, Madrid, Spain., Cortés-Ledesma F; Centro Andaluz de Biologia Molecular y Medicina regenerativa (CABIMER) - CSIC, Universidad de Sevilla, Universidad Pablo de Olavide, Sevilla, Spain., Sastre L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain.; CIBER de Enfermedades Raras, Madrid, Spain., Perona R; Instituto de Investigaciones Biomédicas CSIC/UAM, IDiPaz, C/ Arturo Duperier, 4, 28029, Madrid, Spain. RPerona@iib.uam.es.; CIBER de Enfermedades Raras, Madrid, Spain. RPerona@iib.uam.es.
Publikováno v:
Cell death and differentiation [Cell Death Differ] 2019 Oct; Vol. 26 (10), pp. 1998-2014. Date of Electronic Publication: 2019 Jan 22.
Autor:
Egusquiaguirre SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115., Yeh JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115., Walker SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115., Frank DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115. Electronic address: david_frank@dfci.harvard.edu.
Publikováno v:
Neoplasia (New York, N.Y.) [Neoplasia] 2018 May; Vol. 20 (5), pp. 489-498. Date of Electronic Publication: 2018 Apr 02.
Autor:
Gartziandia O; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain; Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium., Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain., Bianco J; Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium; Integrated Center for Cell Therapy and Regenerative Medicine, International Clinical Research Center (FNUSA-ICRC), St. Anne's University Hospital Brno, Pekařská 53, Brno 656 91, Czech Republic., Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain., Hernandez RM; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz 01006, Spain., Préat V; Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium. Electronic address: veronique.preat@uclouvain.be., Beloqui A; Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium. Electronic address: ana.beloqui@uclouvain.be.
Publikováno v:
International journal of pharmaceutics [Int J Pharm] 2016 Feb 29; Vol. 499 (1-2), pp. 81-89. Date of Electronic Publication: 2015 Dec 22.
Autor:
Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain., Beziere N; Institute for Biological and Medical Imaging, Technische Universität München and Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Munich, Germany., Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain., Hernández RM; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain., Ntziachristos V; Institute for Biological and Medical Imaging, Technische Universität München and Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Munich, Germany., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain.; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain.
Publikováno v:
Contrast media & molecular imaging [Contrast Media Mol Imaging] 2015 Nov-Dec; Vol. 10 (6), pp. 421-7. Date of Electronic Publication: 2015 May 27.
Autor:
Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Manguán-García C; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain., Pintado-Berninches L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain., Iarriccio L; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain; Advanced Medical Projects, Madrid, Spain., Carbajo D; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Institut de Recerca Biomédica, Barcelona, Spain; Unitat de Química Combinatòria, Parc Científic de Barcelona, Barcelona, Spain., Albericio F; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Institut de Recerca Biomédica, Barcelona, Spain., Royo M; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain; Unitat de Química Combinatòria, Parc Científic de Barcelona, Barcelona, Spain., Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Hernández RM; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain., Perona R; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Madrid, Spain. Electronic address: rperona@iib.uam.es., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain. Electronic address: manoli.igartua@ehu.es.
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2015 Apr; Vol. 91, pp. 91-102. Date of Electronic Publication: 2015 Feb 07.
Autor:
Egusquiaguirre SP, Pedraz JL, Hernandez RM, Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. manoli.igartua@ehu.es.
Publikováno v:
Mini reviews in medicinal chemistry [Mini Rev Med Chem] 2015; Vol. 15 (6), pp. 490-502.
Autor:
Egusquiaguirre SP; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, Faculty of Pharmacy, Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain. Electronic address: susanapatricia.egusquiaguirre@ehu.es., Manguán-García C; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Arturo Duperier, 4, 28029 Madrid, Spain. Electronic address: cmanguan@iib.uam.es., Perona R; Instituto de Investigaciones Biomédicas CSIC/UAM, IDIPaz and CIBER de Enfermedades Raras CIBERER, Arturo Duperier, 4, 28029 Madrid, Spain. Electronic address: rperona@iib.uam.es., Pedraz JL; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, Faculty of Pharmacy, Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain. Electronic address: joseluis.pedraz@ehu.es., Hernández RM; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, Faculty of Pharmacy, Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain. Electronic address: rosa.hernandez@ehu.es., Igartua M; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, Faculty of Pharmacy, Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain. Electronic address: manoli.igartua@ehu.es.
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2014 Dec 01; Vol. 972, pp. 95-101. Date of Electronic Publication: 2014 Oct 05.